Brand Name
Pegasys
Generic Name
PEGinterferon Alfa-2A
View Brand Information FDA approval date: October 16, 2002
Classification: Interferon alpha
Form: Injection
What is Pegasys (PEGinterferon Alfa-2A)?
PEGASYS is an inducer of the innate immune response indicated for the treatment of Chronic Hepatitis C .
Approved To Treat
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
A Pilot Study of the Combination of VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis B
Background: Chronic hepatitis B virus (HBV) infection affects 292 million people worldwide; 887,000 die each year from cirrhosis, liver cancer, and related issues. Treatment options are limited.